Bacteriophage Cocktails for Multi-Drug Resistant Infections

AmpliPhi Biosciences is at the forefront of phage therapy research in 2024, developing bacteriophage cocktails to target some of the most dangerous drug-resistant bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae. These bacteria are known for their resistance to multiple antibiotics, making infections incredibly difficult to treat. AmpliPhi’s cocktail approach involves using a combination of bacteriophages that can target different strains of these resistant bacteria.

Current trials aim to assess the safety and efficacy of these cocktails in treating chronic, multi-drug resistant infections. By utilizing a mixture of phages, researchers hope to overcome the limitations of single-phage therapies, which may not be broad enough to tackle all bacterial variants in an infection. If successful, these phage cocktails could provide a much-needed alternative for patients with persistent infections that have no other treatment options​.